Connect with us

Business

Inside Biogen’s scramble to sell Aduhelm: Project ‘Javelin’ and pressure to ID as many patients as possible – Endpoints News

In anticipation of Aduhelm’s approval for Alzheimer’s in June, Biogen employees were directed to identify and guarantee treatment…

Published

on

Article feature image
ADVERTISEMENT

As the saga over how to pay for Aduhelm plays out, biopharma companies are now looking closely at how Biogen was able to keep such a special relationship with FDA officials ahead of the drug’s accelerated approval, and whether or not they might be able…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

Article feature image
3 Underrated Warren Buffett Stocks That Are Smart Buys Right Now – Motley Fool
Article feature image
3 Top Stocks That Just Went on Sale – Motley Fool
Article feature image
A Cash-Strapped Corner of China Finds a Financial Tonic—Hard Liquor – The Wall Street Journal